Several randomized clinical studies of anti-EGFR therapy reported that fewer than 20% of metastatic TNBCs showed response to anti-EGFR therapy [45], [46] and the use of these therapies for targeted breast cancer treatment has been controversial. The gene discussed is EGFR; the disease is breast cancer.